CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced financial results for the third quarter ended September 30, 2015 and corporate highlights.
“Catabasis made important advancements in both of our clinical-stage programs during the third quarter of 2015,” commented Jill C. Milne, Ph.D., chief executive officer of Catabasis.
Help employers find you! Check out all the jobs and post your resume.
